Navigation Links
Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO
Date:9/20/2011

WOBURN, Mass., Sept. 20, 2011 /PRNewswire/ -- Intrinsic Therapeutics, a medical device company focused on developing therapies to address the spine market's many unmet needs, today announced that Cary Hagan has been appointed President and Chief Executive Officer. Mr. Hagan brings over 20 years of experience in the orthopedic implant field with significant expertise in product development, commercialization and global marketing strategy. Greg Lambrecht, Founder and Board Member of Intrinsic, is actively continuing at the company as Executive Director.

"Cary's proven success in bringing new technologies to the global market makes him an ideal choice to lead Intrinsic's next stage of growth as we expand our international clinical and commercial activity," said Mr. Lambrecht. "I look forward to working closely with him to continue to improve the outcomes of the most frequently performed spinal procedures with our innovative Barricaid® anular closure products and extend our operations to new markets."

Mr. Hagan joins Intrinsic from Wright Medical, where he was most recently Senior Vice President, Commercial Operations, Europe, Middle East and Africa.  He began his career at Wright Medical in 1989 and advanced through a series of sales and marketing positions with increasing responsibility.  As Product Manager and then Senior Director of Biologics, Mr. Hagan was pivotal in the rapid growth of Wrights Orthobiologics program from "point zero" to market segment leader.  Later as Vice President Marketing, Global OrthoRecon, he oversaw a turnaround in Wright's Hip and Knee growth rates to roughly two times the industry average.  Mr. Hagan's most recent experience as Sr. Vice President, Commercial Operations for Europe, Middle-East and Africa, gave him full management and P&L responsibility for Wright's EMEA operations.

"The opportunity to engineer and execute a global market-creation strategy in an untouched addressable annual market of approximately 900,000 patients is both rare and exciting," said Mr. Hagan. "The Barricaid® device has the potential to substantially reduce cases of recurrent herniation and back pain associated with failed discectomy -- an outcome that could result in a multi-billion dollar economic benefit in the U.S. alone.  I'm thrilled to join Intrinsic as we bring this revolutionary device into new global markets."

"After performing approximately 1000 implantations since inception, the Intrinsic team has demonstrated that the Barricaid device offers patients a compelling new therapy for anular repair," said NEA General Partner Ryan Drant, who serves on Intrinsic's board of directors. "We look forward to continuing to support both Cary and Greg as they continue to grow our business and strive to improve clinical outcomes for the hundreds of thousands of patients with lumbar disc herniations."

About Intrinsic Therapeutics, Inc.

Intrinsic Therapeutics, Inc., based in Woburn, MA, is a medical device company focused on developing innovative therapies that address the spine market's many unmet clinical needs. The company's first product, Barricaid, is a revolutionary spinal implant that was developed to treat patients undergoing surgery for herniated lumbar discs.

For more information please contact:
Scott LeBlanc - Director of Finance
Intrinsic Therapeutics, Inc.
IR@in-thera.com
+1 (781) 932-0222


'/>"/>
SOURCE Intrinsic Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
2. Intrinsic Enrolls First Patient in Barricaid® Trial
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
(Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... According to ... In an industry filled with chemical-laden beauty products, one company is going against the ... for you: Mad Hippie. The rising star in the green space is proud to ...
(Date:5/26/2016)... Lake MN (PRWEB) , ... May 26, 2016 , ... ... Stance Angle chair , furniture that may support women during pregnancy. Potential benefits ... legs and feet, improved rest and comfort and healthier levels of sitting and standing. ...
(Date:5/25/2016)... (PRWEB) , ... May 26, 2016 , ... The United ... treatment of androgenetic alopecia in both men and women. To date, the company is ... with FDA clearance for any adult who suffers with androgenetic alopecia. , “This ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
(Date:5/25/2016)... Kansas City, MO (PRWEB) , ... May 25, 2016 , ... ... professional, collegiate, and amateur athletics, The National Center for Drug Free Sport (Drug Free ... Drug Free Sport”. This conference, to be held July 12 – 13 in Kansas ...
Breaking Medicine News(10 mins):